|Tested species reactivity||Human|
|Host / Isotype||Rabbit / IgG|
|Immunogen||A 13 amino acid peptide from near the center of human PAK5.|
|Purification||Antigen affinity chromatography|
|Contains||0.02% sodium azide|
|Storage Conditions||Maintain refrigerated at 2-8°C for up to 3 months. For long term storage store at -20°C|
|Tested Applications||Dilution *|
|Immunocytochemistry (ICC)||2 µg/ml|
|Immunofluorescence (IF)||10 ug/ml|
|Western Blot (WB)||2-4 ug/ml|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
A suggested positive control is T24 cell lysate.
PA5-20232 can be used with blocking peptide PEP-0368.
The p21-activated kinases (PAKs) are serine-threonine kinases that bind to the active forms of Cdc42 and Rac. They are divided into two groups, the first of which include PAK1, 2 and 3, and can be activated by Cdc42/Rac binding. Group 1 PAKs contain an autoinhibitory domain whose activity is regulated by Cdc42/Rac binding. The group 1 PAKs are known to be involved in cellular processes such as gene transcription, apoptosis, and cell morphology and motility. Much less is known about the second group, which includes PAK4, 5 and 6. These proteins are not activated by Cdc42/Rac binding. PAK5 was initially identified as a kinase expressed primarily in brain that while possessing a kinase domain and GTPase binding domain similar to PAK4 and PAK6, is completely different from both. Expression of PAK5 in neural based cell lines resulted in neurite outgrowth suggesting that PAK5 may be involved in regulating the cytoskeletal changes necessary for promoting neurite outgrowth. Other experiments suggest that unlike the other PAKs, PAK5 may inhibit apoptosis by phosphorylating the Bcl-2 family member Bad.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.